Praeventix

Praeventix is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel serotonergic therapeutics for diseases with high unmet need. The company's lead program, PRA-523, is a potential first-in-class, topically administered 5-HT7 receptor antagonist currently in Phase 1 clinical trials for the treatment of chronic pruritus associated with atopic dermatitis. Praeventix is also advancing preclinical programs targeting 5-HT7 for inflammatory bowel disease and cocaine use disorder. Founded on research from Temple University and backed by Tellus BioVentures, the company utilizes its expertise in G-protein-coupled receptor (GPCR) modulation to develop peripherally restricted small molecules. Their approach aims to provide targeted relief for patients suffering from serotonergic-driven inflammatory and neurodegenerative conditions.